|
Vetoquinol SA is an international veterinary pharmaceutical company that develops, manufactures, and markets medicines and non-medicinal products for companion animals and livestock. Founded in 1933, the company focuses on a core portfolio of 'Essentiels' products, which include antiparasitics, antibiotics, and nutraceuticals for dogs, cats, cattle, and pigs. The group serves veterinarians, pet owners, and farmers across Europe, the United States, and the Asia-Pacific region, operating through direct subsidiaries and distributors. Vetoquinol operates manufacturing sites in France, Poland, Brazil, and Canada, and acquired Bioniche Animal Health in 2014 to expand its footprint in Australia. The company provides digital tools and training services to support veterinary practices, maintaining a business model centered on long-term partnerships with veterinary professionals. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage vetoquinol.com |
| Sector Healthcare | IR page vetoquinol.com/en/investors | |
|
Tags
veterinary pharmaceuticals, companion animal health, livestock health, antiparasitics, nutraceuticals, animal diagnostics, veterinary services, Bioniche Animal Health
|
Press page vetoquinol.com/en/news |
Metrics
| Valuation | |
|---|---|
| Market cap | € 826.147M |
| Market cap (USD) | $ 919.253M |
| P/E | 14.40 |
| PEG | 2.35 |
| P/BV | 1.40 |
| P/S | 1.53 |
| P/OCF | 11.46 |
| P/FCF | 15.01 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 9.8% |
| ROI | 9.7% |
| ROIC | 9.5% |
| Profit margin | 10.9% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 6.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 0.03% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 525.686M | 539.196M | 529.271M | 539.779M | 521.272M | 427.467M | 395.99M | 367.941M | 352.173M | 350.354M | 342.612M | — | — | — | — | — |
| Net profit | 57.36M | 58.685M | 55.56M | 47.995M | 62.861M | 19.221M | 28.247M | 36.226M | 34.838M | 27.83M | 24.16M | — | — | — | — | — |
| Free cash flow | 55.054M | 71.281M | 74.495M | 45.884M | 75.895M | 81.893M | — | — | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Trade receivables (EUR) | 88.6M | 87.2M | 85.4M | 99.2M | 94.8M | 99M |
| ↳ YoY growth | -1.6% | -2.1% | +16.2% | -4.4% | +4.4% | |
| ↳ 5y CAGR | +2.2% | |||||
| Borrowings, current (EUR) | 112M | 3.92M | 3.3M | 2.99M | 4.39M | 1.64M |
| Borrowings, non-current (EUR) | 176,000 | 187,000 | 179,000 | 172,000 | 178,000 | 158,000 |
| Lease liabilities (EUR) | 12.4M | 11.3M | 13.9M | 14.5M | 16.6M | 13.5M |
| Cash and deposits (EUR) | 129M | 69M | 93.7M | 147M | 206M | 221M |
| Intangible assets (EUR) | 175M | 179M | 169M | 154M | 142M | 130M |
| Right-of-use assets (EUR) | 12.2M | 11M | 13.7M | 14M | 16M | 12.9M |
| Net debt (borrowings + leases - cash) (EUR) | -4.59M | -53.6M | -76.3M | -130M | -185M | -206M |
| Cash flow detail | ||||||
| Operating cash flow (EUR) | 92.2M | 89.7M | 62.9M | 89.4M | 85.8M | 72.1M |
| Purchases of property, plant and equipment (EUR) | -10.3M | -13.8M | -17M | -14.9M | -14.5M | -17M |
| Purchases of intangible assets (EUR) | -135M | -18.6M | -5.53M | -4.11M | -3.13M | -3.71M |
| Dividends paid (cash effect) (EUR) | -4.49M | -5.91M | -9.47M | -9.47M | -10.1M | -10.4M |
| Interest paid (cash effect) (EUR) | -601,000 | -594,000 | -737,000 | -477,000 | -481,000 | -661,000 |
| Income taxes paid (cash effect) (EUR) | -12.5M | -26.2M | -31.9M | -21.9M | -21.8M | -26.8M |
| Share-based compensation (EUR) | 78,000 | 129,000 | 51,000 | 0.00 | 0.00 | 0.00 |
| Free cash flow (OCF - PPE - intangibles) (EUR) | -53.2M | 57.3M | 40.4M | 70.4M | 68.1M | 51.3M |
| Income detail | ||||||
| Total comprehensive income (EUR) | -9.41M | 75.2M | 52.9M | 51.8M | 62M | 38.8M |
| Comprehensive income to owners (EUR) | -9.42M | 75.2M | 52.9M | 51.8M | 62M | 38.9M |
| Reported | Apr 22, 2022 | Apr 22, 2022 | Apr 13, 2023 | Apr 24, 2024 | Apr 24, 2025 | Apr 29, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpRegulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Vetoquinol SA
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.